Cetuximab in small bowel adenocarcinoma: a new friend?

Br J Cancer. 2010 Oct 12;103(8):1305; author reply 1306. doi: 10.1038/sj.bjc.6605898. Epub 2010 Sep 14.
No abstract available

Publication types

  • Case Reports
  • Evaluation Study
  • Letter
  • Comment

MeSH terms

  • Adenocarcinoma / mortality
  • Adenocarcinoma / pathology
  • Adenocarcinoma / therapy*
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Camptothecin / administration & dosage
  • Camptothecin / analogs & derivatives
  • Cetuximab
  • Combined Modality Therapy
  • Female
  • Humans
  • Immunotherapy
  • Intestinal Neoplasms / mortality
  • Intestinal Neoplasms / pathology
  • Intestinal Neoplasms / therapy*
  • Intestine, Small / pathology
  • Irinotecan
  • Male
  • Middle Aged
  • Survival

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Irinotecan
  • Cetuximab
  • Camptothecin